Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PET Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05619016
What this trial is testing

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Who this might be right for
Esophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more
Karolinska University Hospital 72
Not applicableStudy completedNCT02286843
What this trial is testing

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Who this might be right for
Breast Cancer MetastasesHER2 Positive Breast
Memorial Sloan Kettering Cancer Center 49
Not applicableStudy completedNCT05797987
What this trial is testing

Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor

Who this might be right for
Breast Cancer
Fudan University 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT05867615
What this trial is testing

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

Who this might be right for
Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 83
Not applicableEnrolling By InvitationNCT06835244
What this trial is testing

Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms

Who this might be right for
PSMA Positive Tumors or Tumor TissuesCancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT03314636
What this trial is testing

Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

Who this might be right for
Myeloma
Oslo University Hospital 53
Post-approval studies (Phase 4)Active Not RecruitingNCT05486182
What this trial is testing

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 153
Not applicableWithdrawnNCT03561324
What this trial is testing

Intraoperative Imaging of a PET Positive Lymph Node(s) Using 18FDG and a Dual-Mode, Hand-Held Intraoperative Imager

Who this might be right for
Head and Neck Neoplasms
University of Arkansas
Not applicableStudy completedNCT03342378
What this trial is testing

PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

Who this might be right for
Squamous Cell CarcinomaOropharynx Cancer
University of Wisconsin, Madison 24
Large-scale testing (Phase 3)UnknownNCT00450203
What this trial is testing

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Who this might be right for
Oesophagogastric Cancer
Professor David Cunningham 1,103
Testing effectiveness (Phase 2)Looking for participantsNCT06335069
What this trial is testing

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

Who this might be right for
Breast CancerBreast NeoplasmsBreast Diseases
Maastricht University Medical Center 20
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Looking for participantsNCT06549465
What this trial is testing

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics 93
Early research (Phase 1)Study completedNCT01420146
What this trial is testing

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

Who this might be right for
Breast NeoplasmsSecondaryHER2 Positive Carcinoma of Breast
Jules Bordet Institute 20
Not applicableLooking for participantsNCT06548529
What this trial is testing

HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC

Who this might be right for
HER2 Positive or Suspicious Positive Tumors
Peking University Cancer Hospital & Institute 30
Not applicableActive Not RecruitingNCT07316439
What this trial is testing

Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 197
Not applicableLooking for participantsNCT06850545
What this trial is testing

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT04009967
What this trial is testing

Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning

Who this might be right for
Prostate Cancer
CHU de Quebec-Universite Laval 30
Testing effectiveness (Phase 2)Study completedNCT01619865
What this trial is testing

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorsNeuroblastoma+1 more
Sue O'Dorisio 223